Advertisement
Canada markets close in 49 minutes
  • S&P/TSX

    22,288.47
    +29.00 (+0.13%)
     
  • S&P 500

    5,185.88
    +5.14 (+0.10%)
     
  • DOW

    38,875.52
    +23.25 (+0.06%)
     
  • CAD/USD

    0.7284
    -0.0037 (-0.50%)
     
  • CRUDE OIL

    78.51
    +0.03 (+0.04%)
     
  • Bitcoin CAD

    86,767.50
    -125.72 (-0.14%)
     
  • CMC Crypto 200

    1,308.84
    -56.29 (-4.13%)
     
  • GOLD FUTURES

    2,322.70
    -8.50 (-0.36%)
     
  • RUSSELL 2000

    2,068.96
    +8.29 (+0.40%)
     
  • 10-Yr Bond

    4.4650
    -0.0240 (-0.53%)
     
  • NASDAQ

    16,336.44
    -12.81 (-0.08%)
     
  • VOLATILITY

    13.37
    -0.12 (-0.89%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6770
    -0.0022 (-0.32%)
     

Abbvie stock falls amid growing biosimilar competition

Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition.

Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance.

This post was written by Angel Smith